SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes - a single center experience
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Jornal Brasileiro de Nefrologia |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002022000300376 |
Resumo: | ABSTRACT Introduction: Kidney transplant recipients are a subgroup of patients at higher risk of critical forms of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection and poor outcomes due to immunosuppression treatment. Herein, we present data from a single center cohort of kidney transplant recipients with SARS-CoV-2 infection. Methods: In a prospective study, baseline characteristics, clinical features, antiviral and immunosuppression management were compared between outpatients and hospitalized patients, during a one-year period. Results: Seventy-seven kidney transplant recipients were analyzed, including outpatients and hospitalized patients, with a median age of 57.7 (IQR 49.7-64.9) years. Twenty-eight (36.4%) were managed as outpatients, while 49 (63.6%) patients required hospital admission. Among hospitalized patients, 18.4% were admitted in ICU, 49% had AKI, and 20.4% died. Immunosuppression adjustments were performed in 95.9% of hospitalized patients, with dose of anti-metabolites adjusted in 83.7%, mTOR inhibitors in 14.3%, calcineurin inhibitors in 12.2%, and corticosteroid therapy in 81.6%. Conclusion: Among hospitalized patients, immunosuppression management included reduction or withdrawal of anti-metabolite and increase of corticosteroid dose. AKI occurred in almost half of patients and mortality in hospitalized patients reached 20%, reflecting greater disease severity than the general population. |
id |
SBN-1_14eb4cc46ba8ad917c0a1ed5d8008c97 |
---|---|
oai_identifier_str |
oai:scielo:S0101-28002022000300376 |
network_acronym_str |
SBN-1 |
network_name_str |
Jornal Brasileiro de Nefrologia |
repository_id_str |
|
spelling |
SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes - a single center experienceKidney TransplantationCOVID-19AntiviralsABSTRACT Introduction: Kidney transplant recipients are a subgroup of patients at higher risk of critical forms of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection and poor outcomes due to immunosuppression treatment. Herein, we present data from a single center cohort of kidney transplant recipients with SARS-CoV-2 infection. Methods: In a prospective study, baseline characteristics, clinical features, antiviral and immunosuppression management were compared between outpatients and hospitalized patients, during a one-year period. Results: Seventy-seven kidney transplant recipients were analyzed, including outpatients and hospitalized patients, with a median age of 57.7 (IQR 49.7-64.9) years. Twenty-eight (36.4%) were managed as outpatients, while 49 (63.6%) patients required hospital admission. Among hospitalized patients, 18.4% were admitted in ICU, 49% had AKI, and 20.4% died. Immunosuppression adjustments were performed in 95.9% of hospitalized patients, with dose of anti-metabolites adjusted in 83.7%, mTOR inhibitors in 14.3%, calcineurin inhibitors in 12.2%, and corticosteroid therapy in 81.6%. Conclusion: Among hospitalized patients, immunosuppression management included reduction or withdrawal of anti-metabolite and increase of corticosteroid dose. AKI occurred in almost half of patients and mortality in hospitalized patients reached 20%, reflecting greater disease severity than the general population.Sociedade Brasileira de Nefrologia2022-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002022000300376Brazilian Journal of Nephrology v.44 n.3 2022reponame:Jornal Brasileiro de Nefrologiainstname:Sociedade Brasileira de Nefrologia (SBN)instacron:SBN10.1590/2175-8239-jbn-2021-0164info:eu-repo/semantics/openAccessSantos,AfonsoSousa,Luís Leite deCalça,RitaLima,AnnaNascimento,CéliaJorge,CristinaAdragão,TeresaBruges,MargaridaPeres,SusanaWeigert,Andréeng2022-09-23T00:00:00Zoai:scielo:S0101-28002022000300376Revistahttp://www.bjn.org.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||jbn@sbn.org.br2175-82390101-2800opendoar:2022-09-23T00:00Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN)false |
dc.title.none.fl_str_mv |
SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes - a single center experience |
title |
SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes - a single center experience |
spellingShingle |
SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes - a single center experience Santos,Afonso Kidney Transplantation COVID-19 Antivirals |
title_short |
SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes - a single center experience |
title_full |
SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes - a single center experience |
title_fullStr |
SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes - a single center experience |
title_full_unstemmed |
SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes - a single center experience |
title_sort |
SARS-CoV-2 infection in kidney transplant recipients: clinical impact and outcomes - a single center experience |
author |
Santos,Afonso |
author_facet |
Santos,Afonso Sousa,Luís Leite de Calça,Rita Lima,Anna Nascimento,Célia Jorge,Cristina Adragão,Teresa Bruges,Margarida Peres,Susana Weigert,André |
author_role |
author |
author2 |
Sousa,Luís Leite de Calça,Rita Lima,Anna Nascimento,Célia Jorge,Cristina Adragão,Teresa Bruges,Margarida Peres,Susana Weigert,André |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Santos,Afonso Sousa,Luís Leite de Calça,Rita Lima,Anna Nascimento,Célia Jorge,Cristina Adragão,Teresa Bruges,Margarida Peres,Susana Weigert,André |
dc.subject.por.fl_str_mv |
Kidney Transplantation COVID-19 Antivirals |
topic |
Kidney Transplantation COVID-19 Antivirals |
description |
ABSTRACT Introduction: Kidney transplant recipients are a subgroup of patients at higher risk of critical forms of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection and poor outcomes due to immunosuppression treatment. Herein, we present data from a single center cohort of kidney transplant recipients with SARS-CoV-2 infection. Methods: In a prospective study, baseline characteristics, clinical features, antiviral and immunosuppression management were compared between outpatients and hospitalized patients, during a one-year period. Results: Seventy-seven kidney transplant recipients were analyzed, including outpatients and hospitalized patients, with a median age of 57.7 (IQR 49.7-64.9) years. Twenty-eight (36.4%) were managed as outpatients, while 49 (63.6%) patients required hospital admission. Among hospitalized patients, 18.4% were admitted in ICU, 49% had AKI, and 20.4% died. Immunosuppression adjustments were performed in 95.9% of hospitalized patients, with dose of anti-metabolites adjusted in 83.7%, mTOR inhibitors in 14.3%, calcineurin inhibitors in 12.2%, and corticosteroid therapy in 81.6%. Conclusion: Among hospitalized patients, immunosuppression management included reduction or withdrawal of anti-metabolite and increase of corticosteroid dose. AKI occurred in almost half of patients and mortality in hospitalized patients reached 20%, reflecting greater disease severity than the general population. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-09-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002022000300376 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002022000300376 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/2175-8239-jbn-2021-0164 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Nefrologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Nefrologia |
dc.source.none.fl_str_mv |
Brazilian Journal of Nephrology v.44 n.3 2022 reponame:Jornal Brasileiro de Nefrologia instname:Sociedade Brasileira de Nefrologia (SBN) instacron:SBN |
instname_str |
Sociedade Brasileira de Nefrologia (SBN) |
instacron_str |
SBN |
institution |
SBN |
reponame_str |
Jornal Brasileiro de Nefrologia |
collection |
Jornal Brasileiro de Nefrologia |
repository.name.fl_str_mv |
Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN) |
repository.mail.fl_str_mv |
||jbn@sbn.org.br |
_version_ |
1752122067408388096 |